» Articles » PMID: 25424036

Testing the Mutant Selection Window Hypothesis in Vitro and in Vivo with Staphylococcus Aureus Exposed to Fosfomycin

Overview
Publisher Springer
Date 2014 Nov 27
PMID 25424036
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of this study was to test the mutant selection window (MSW) hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin. With the in vitro time-kill studies, S. aureus ATCC 29213 [with a minimal concentration that inhibits colony formation by 99% (MIC99) of 2.2 μg/mL and a mutant prevention concentration (MPC) of 57.6 μg/mL] lost fosfomycin susceptibility at antibiotic concentrations (2×, 4×, and 8× MIC) that are between the lower and upper boundaries of the MSW. In the tissue-cage model, S. aureus was exposed to fosfomycin pharmacokinetics at concentrations below the MIC99, between the MIC99 and the MPC, and above the MPC, respectively. Changes in susceptibility and counts of total and resistant viable bacteria were monitored in tissue-cage fluid obtained daily. However, the selection of resistant mutants was not observed during antibacterial treatment and 48 h after the termination of fosfomycin treatment, regardless of the fosfomycin dosage. Besides, we found no differences between the in vitro-isolated mutant and its sensitive parental strain, which indicates the absence of fitness cost of fosfomycin resistance in S. aureus ATCC 29213. These findings demonstrate that agar plate determinations do not fit the MSW for fosfomycin treatment of rabbits infected with S. aureus ATCC 29213; therefore, the existence of the window must be demonstrated not only in vitro but also in vivo. Further research is needed on the exact mechanism of resistance.

Citing Articles

Antibiotics with antibiofilm activity - rifampicin and beyond.

Ferreira L, Pos E, Nogueira D, Ferreira F, Sousa R, Abreu M Front Microbiol. 2024; 15:1435720.

PMID: 39268543 PMC: 11391936. DOI: 10.3389/fmicb.2024.1435720.


In Vitro Resistance-Predicting Studies and In Vitro Resistance-Related Parameters-A Hit-to-Lead Perspective.

Krajewska J, Tyski S, Laudy A Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204172 PMC: 11357384. DOI: 10.3390/ph17081068.


Intravenous Fosfomycin for Systemic Multidrug-Resistant Infections.

Pipitone G, Di Bella S, Maraolo A, Granata G, Gatti M, Principe L Antibiotics (Basel). 2023; 12(12).

PMID: 38136687 PMC: 10741068. DOI: 10.3390/antibiotics12121653.


Alternate Antimicrobial Therapies and Their Companion Tests.

Kalpana S, Lin W, Wang Y, Fu Y, Wang H Diagnostics (Basel). 2023; 13(15).

PMID: 37568853 PMC: 10417861. DOI: 10.3390/diagnostics13152490.


Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the Determination of the Antimicrobial Potency of Compounds.

Krajewska J, Tyski S, Laudy A Antimicrob Agents Chemother. 2023; 67(5):e0137322.

PMID: 37022162 PMC: 10190592. DOI: 10.1128/aac.01373-22.


References
1.
Poeppl W, Tobudic S, Lingscheid T, Plasenzotti R, Kozakowski N, Lagler H . Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model. Antimicrob Agents Chemother. 2011; 55(11):4999-5003. PMC: 3194995. DOI: 10.1128/AAC.00584-11. View

2.
Croisier D, Etienne M, Bergoin E, Charles P, Lequeu C, Piroth L . Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob Agents Chemother. 2004; 48(5):1699-707. PMC: 400524. DOI: 10.1128/AAC.48.5.1699-1707.2004. View

3.
LaPlante K, Rybak M . Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004; 48(12):4665-72. PMC: 529225. DOI: 10.1128/AAC.48.12.4665-4672.2004. View

4.
Allen G, Kaatz G, Rybak M . Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2003; 47(8):2606-14. PMC: 166082. DOI: 10.1128/AAC.47.8.2606-2614.2003. View

5.
Hamilton-Miller J . In vitro activity of fosfomycin against 'problem' gram-positive cocci. Microbios. 1992; 71(287):95-103. View